Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $768.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price upped by Morgan Stanley from $767.00 to $768.00 in a research report released on Friday,Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on REGN. Jefferies Financial Group boosted their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. HSBC assumed coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 price objective for the company. Sanford C. Bernstein increased their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Finally, Canaccord Genuity Group boosted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $779.45.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $741.29 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $790.98. The firm’s 50-day simple moving average is $664.44 and its 200-day simple moving average is $592.76. The firm has a market cap of $77.91 billion, a PE ratio of 17.75, a price-to-earnings-growth ratio of 2.12 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period in the previous year, the company earned $12.46 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP raised its position in shares of Regeneron Pharmaceuticals by 50.5% during the 3rd quarter. Allworth Financial LP now owns 1,496 shares of the biopharmaceutical company’s stock worth $841,000 after buying an additional 502 shares in the last quarter. IFP Advisors Inc increased its stake in shares of Regeneron Pharmaceuticals by 14.2% during the third quarter. IFP Advisors Inc now owns 1,405 shares of the biopharmaceutical company’s stock valued at $790,000 after acquiring an additional 175 shares during the period. Swiss Life Asset Management Ltd raised its holdings in Regeneron Pharmaceuticals by 112.0% during the third quarter. Swiss Life Asset Management Ltd now owns 23,658 shares of the biopharmaceutical company’s stock worth $13,302,000 after purchasing an additional 12,500 shares in the last quarter. Cambria Investment Management L.P. lifted its position in Regeneron Pharmaceuticals by 21.8% in the third quarter. Cambria Investment Management L.P. now owns 3,090 shares of the biopharmaceutical company’s stock worth $1,737,000 after purchasing an additional 554 shares during the period. Finally, Pointe Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 37.0% during the 3rd quarter. Pointe Capital Management LLC now owns 719 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 194 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.